MX2022016227A - Composiciones que tienen aplicaciones neuroregenerativas. - Google Patents
Composiciones que tienen aplicaciones neuroregenerativas.Info
- Publication number
- MX2022016227A MX2022016227A MX2022016227A MX2022016227A MX2022016227A MX 2022016227 A MX2022016227 A MX 2022016227A MX 2022016227 A MX2022016227 A MX 2022016227A MX 2022016227 A MX2022016227 A MX 2022016227A MX 2022016227 A MX2022016227 A MX 2022016227A
- Authority
- MX
- Mexico
- Prior art keywords
- neuroregenerative
- compositions
- applications
- neurodegenerative
- lactoferrin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000003018 neuroregenerative effect Effects 0.000 title 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 102000010445 Lactoferrin Human genes 0.000 abstract 2
- 108010063045 Lactoferrin Proteins 0.000 abstract 2
- 102000004338 Transferrin Human genes 0.000 abstract 2
- 108090000901 Transferrin Proteins 0.000 abstract 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 abstract 2
- 229940078795 lactoferrin Drugs 0.000 abstract 2
- 235000021242 lactoferrin Nutrition 0.000 abstract 2
- 230000000626 neurodegenerative effect Effects 0.000 abstract 2
- 239000012581 transferrin Substances 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 210000003061 neural cell Anatomy 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
En el presente documento se dan a conocer composiciones farmacéuticas que contienen transferrina o lactoferrina para utilizar en la promoción o inducción de la generación de nuevas células neurales en un paciente que ha sufrido un evento neurodegenerativo. El evento neurodegenerativo puede ser causado por una enfermedad neurodegenerativa, tal como enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington o esclerosis lateral amiotrófica. De manera ideal, la transferrina y/o lactoferrina tienen una saturación baja de hierro.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063049486P | 2020-07-08 | 2020-07-08 | |
| PCT/EP2021/068873 WO2022008609A1 (en) | 2020-07-08 | 2021-07-07 | Compositions having neuroregenerative applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016227A true MX2022016227A (es) | 2023-02-01 |
Family
ID=77126778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016227A MX2022016227A (es) | 2020-07-08 | 2021-07-07 | Composiciones que tienen aplicaciones neuroregenerativas. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230263863A1 (es) |
| EP (1) | EP4178554A1 (es) |
| JP (1) | JP2023532557A (es) |
| KR (1) | KR20230038195A (es) |
| CN (1) | CN115996743A (es) |
| AR (1) | AR122900A1 (es) |
| AU (1) | AU2021306631A1 (es) |
| BR (1) | BR112022026567A2 (es) |
| CA (1) | CA3182958A1 (es) |
| CL (1) | CL2022003591A1 (es) |
| IL (1) | IL299183A (es) |
| MX (1) | MX2022016227A (es) |
| TW (1) | TW202216184A (es) |
| WO (1) | WO2022008609A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4052723A1 (en) * | 2021-03-02 | 2022-09-07 | Grifols Worldwide Operations Limited | Alpha-1 antitrypsin dosing regimen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7618615B2 (en) | 2004-08-13 | 2009-11-17 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
| CN100577798C (zh) * | 2007-01-30 | 2010-01-06 | 中国人民解放军军事医学科学院基础医学研究所 | 细胞因子和化合物构成的组方，其促进神经再生作用及在神经系统疾患研究和诊治中的作用 |
| WO2012149111A1 (en) * | 2011-04-26 | 2012-11-01 | The Regents Of The University Of California | Methods of promoting cns neuronal repair by inhibiting lrp-1 |
| US9492509B2 (en) * | 2011-11-11 | 2016-11-15 | Fundaciö Institut D'investigació En Ciències De La Salut Germans Trias I Pujol | Apotransferrin for the treatment of brain stroke |
| EP3795171B1 (en) | 2014-07-11 | 2024-04-10 | Grifols Worldwide Operations Limited | Transferrin for use in kidney transplantation |
| CN106511979A (zh) * | 2016-12-16 | 2017-03-22 | 青岛大学 | 乳铁蛋白在制备帕金森治疗药物中的应用 |
-
2021
- 2021-07-07 AU AU2021306631A patent/AU2021306631A1/en active Pending
- 2021-07-07 IL IL299183A patent/IL299183A/en unknown
- 2021-07-07 WO PCT/EP2021/068873 patent/WO2022008609A1/en unknown
- 2021-07-07 MX MX2022016227A patent/MX2022016227A/es unknown
- 2021-07-07 TW TW110124874A patent/TW202216184A/zh unknown
- 2021-07-07 BR BR112022026567A patent/BR112022026567A2/pt unknown
- 2021-07-07 US US18/004,231 patent/US20230263863A1/en active Pending
- 2021-07-07 KR KR1020237001003A patent/KR20230038195A/ko unknown
- 2021-07-07 AR ARP210101905A patent/AR122900A1/es unknown
- 2021-07-07 EP EP21748519.2A patent/EP4178554A1/en active Pending
- 2021-07-07 CN CN202180045248.8A patent/CN115996743A/zh active Pending
- 2021-07-07 JP JP2022581608A patent/JP2023532557A/ja active Pending
- 2021-07-07 CA CA3182958A patent/CA3182958A1/en active Pending
-
2022
- 2022-12-15 CL CL2022003591A patent/CL2022003591A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021306631A1 (en) | 2023-02-02 |
| US20230263863A1 (en) | 2023-08-24 |
| IL299183A (en) | 2023-02-01 |
| CN115996743A (zh) | 2023-04-21 |
| TW202216184A (zh) | 2022-05-01 |
| KR20230038195A (ko) | 2023-03-17 |
| BR112022026567A2 (pt) | 2023-01-17 |
| WO2022008609A1 (en) | 2022-01-13 |
| CL2022003591A1 (es) | 2023-07-07 |
| EP4178554A1 (en) | 2023-05-17 |
| JP2023532557A (ja) | 2023-07-28 |
| CA3182958A1 (en) | 2022-01-13 |
| AR122900A1 (es) | 2022-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502028A1 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| MX2019002211A (es) | Composiciones de nicotinamida ribosido y pterostilbeno y metodos para el tratamiento de trastornos neurodegenerativos. | |
| SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| MX2019001286A (es) | Composicion de cannabis. | |
| PH12020550432A1 (en) | Compositions of phosphorylated tau peptides and uses thereof | |
| BR112019005428A2 (pt) | agentes, usos e métodos de tratamento | |
| BRPI0513317A (pt) | ciclosporinas para tratar doença de alzheimer | |
| MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
| ZA201903226B (en) | Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same | |
| MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
| MX2019006495A (es) | Tratamiento de enfermedades neurologicas. | |
| UY37580A (es) | Compuestos novedosos que inhiben la actividad de cinasa lrrk2 | |
| MX2022016227A (es) | Composiciones que tienen aplicaciones neuroregenerativas. | |
| PH12021550043A1 (en) | Use of riluzole prodrugs to treat alzheimer's disease | |
| PH12020551779A1 (en) | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| MX340564B (es) | Isoformas de neurregulina solubles activas modificadas post-traduccionalmente. | |
| PH12019501006A1 (en) | Synergistic dietary supplement compositions for improving brain health | |
| MY194272A (en) | Anti-msln antibody and pharmaceutical composition for cancer treatment comprising same | |
| WO2019070727A3 (en) | Nonviral gene transfer to the suprachoroidal space | |
| MX2022016226A (es) | Composiciones que tienen aplicaciones neuroregenerativas. | |
| MX2022006674A (es) | Composiciones de celulas t reguladoras (treg) y metodos para tratar enfermedades neurodegenerativas. | |
| WO2021011875A8 (en) | Compositions and methods for treating skin conditions | |
| MX2021002936A (es) | Uso de recambio plasmatico de bajo volumen para el tratamiento de la enfermedad de alzheimer en etapas temprana y moderada. | |
| MX2020010425A (es) | Composicion isotopicamente modificada y sus usos terapeuticos. |